Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.
EP. 1: Optimizing Transitions to BiosimilarsOctober 26th 2021
Ryan Haumschild, PharmD, MS, MBA, discusses optimizing the transition to biosimilars, covering from what patients to look for as candidates to the process of switching a patient from a brand to a biosimilar to the importance of patient education.
EP. 2: Optimizing Transitions to Biosimilars ContinuedOctober 26th 2021
Ryan Haumschild, PharmD, MS, MBA, continues focusing on transition optimization, explaining how to efficiently create your inventory, how his use of biosimilars will change in the future, and offering advice to those looking to transition to biosimilars.
EP. 7: Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care PlansNovember 16th 2021
Two experts explain if they had to create any incentives for health care providers to prescribe biosimilars, whether they encountered challenges with their electronic health records, and if their biosimilar programs impacted their clinical pathway/care plans.
EP. 8: Evaluating Biosimilar Programs and FormulariesNovember 16th 2021
Kathy Oubre, MS, closes this Insights program by evaluating her organization’s biosimilars program and formularies, including third party preference on the use of specific biosimilars and whether biosimilars can be used outside of their indications.